"Fluoxetine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
| Descriptor ID |
D005473
|
| MeSH Number(s) |
D02.092.831.280
|
| Concept/Terms |
Fluoxetine- Fluoxetine
- Fluoxetin
- N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
|
Below are MeSH descriptors whose meaning is more general than "Fluoxetine".
Below are MeSH descriptors whose meaning is more specific than "Fluoxetine".
This graph shows the total number of publications written about "Fluoxetine" by people in this website by year, and whether "Fluoxetine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 1 | 2 |
| 1995 | 1 | 0 | 1 |
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 1 | 2 |
| 1999 | 2 | 0 | 2 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 1 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fluoxetine" by people in Profiles.
-
Mutations of tyrosine 467 in the human norepinephrine transporter attenuate HIV-1 Tat-induced inhibition of dopamine transport while retaining physiological function. PLoS One. 2022; 17(9):e0275182.
-
Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017 Aug; 76(8):1327-1339.
-
The ?2-adrenoceptor agonist formoterol stimulates mitochondrial biogenesis. J Pharmacol Exp Ther. 2012 Jul; 342(1):106-18.
-
Do pharmacological and behavioral interventions differentially affect treatment outcome for children with social phobia? Behav Modif. 2011 Sep; 35(5):451-67.
-
The relations among measurements of informant discrepancies within a multisite trial of treatments for childhood social phobia. J Abnorm Child Psychol. 2010 Apr; 38(3):395-404.
-
Mediators and moderators of outcome in the behavioral treatment of childhood social phobia. J Am Acad Child Adolesc Psychiatry. 2009 Sep; 48(9):945-953.
-
SET-C versus fluoxetine in the treatment of childhood social phobia. J Am Acad Child Adolesc Psychiatry. 2007 Dec; 46(12):1622-32.
-
Acute stress-mediated increases in extracellular glutamate levels in the rat amygdala: differential effects of antidepressant treatment. Eur J Neurosci. 2007 May; 25(10):3109-14.
-
Pretreatment attrition and childhood social phobia: Parental concerns about medication. J Anxiety Disord. 2006; 20(8):1133-47.
-
Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. J Clin Psychopharmacol. 2004 Feb; 24(1):4-10.